Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Instagram Outage Disrupts Thousands of U.S. Users 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
Merck KGaA has signed partnership deals with BenevolentAI and Exscientia for its AI-driven drug discovery push. The German science and technology company is collaborating with these AI drug discovery firms to strengthen its own capabilities in designing and creating new drugs using artificial intelligence.
As per Fierce BioTech, Merck KGaA is betting on an AI-enabled future for drug discovery the new deals with BenevolentAI and Exscientia are part of its strategy to meet its own goals. Based on the reports, the contracts are worth over $30 million upfront and up to $1 billion in possible milestone arrangements.
In any case, with its collaborations with two leading AI drug discovery groups, Merck just bolstered its chances of yielding successful results for its targeted development and production of new drugs on three leading categories in the medical fields, which are immunology, neuroinflammation, cancer, and neurology
Merck’s global head of R&D also said that the incorporation of science, AI, and data could allow them to find and produce “previously unimaginable medical breakthroughs.” Although the AI-enabled drug discovery method is still in the early stages, the company is positive that it will achieve its goals while also becoming a pioneer in this field.
“With the convergence of science, data, and AI, we're determined to fast-track the development of new and truly innovative candidates, forging a path to previously unimaginable medical breakthroughs,” Merck’s global head of research and development and chief medical officer for the healthcare business unit, Danny Bar-Zohar, said in a press release.
He added, “The partnerships with industry-leading AI technology firms BenevolentAI and Exscientia will complement our internal research capabilities and expertise, aligning with our broader strategy to enhance R&D productivity and the output of our pipeline in a sustainable manner.”
Photo by: Merck Group Media Gallery
